Here is a thing about cancer care that sounds like it can't possibly be true, and then turns out to be more or less true: the opioids that keep patients comfortable may be undercutting the immunotherapy meant to keep them alive. Roughly 45% of patients on immune checkpoint inhibitors also take opioids for pain. A 2022 study across about 4,000 patients found that opioid use tracked with a roughly 50% reduction in the efficacy of those checkpoint inhibitors. That is not a rounding error. That is half the drug's benefit, potentially walking out the door with the painkiller.
Glycyx, a San Francisco biopharmaceutical company founded in 2020, exists because someone read that finding and asked the obvious follow-up question that nobody had turned into a drug: what if you could block the immune suppression without blocking the pain relief? The whole company is that sentence, developed into a clinical program.
The mechanism has a name - opioid-induced immunodeficiency, or OII - and it works roughly like this. Opioids don't only bind receptors in the brain. There are mu-opioid receptors on immune cells out in the body, and when opioids activate them, they help keep T-cells from infiltrating tumors while nudging along the blood-vessel growth and immune exhaustion that tumors love. The tumor stays "cold," which is oncology's word for a tumor the immune system has been talked out of attacking. Checkpoint inhibitors are supposed to heat those tumors back up. Opioids, it seems, keep turning the thermostat back down.
The molecule at the center of all this, axelopran, was not invented for cancer. It was originally developed - by Theravance Biopharma, which licensed it to Glycyx - as a peripherally restricted opioid antagonist, the kind of drug once studied for opioid-induced constipation. "Peripherally restricted" is the load-bearing phrase: axelopran works outside the brain and central nervous system. It blocks opioid signaling on immune cells while leaving the pain relief in the brain intact. Patients keep their comfort; the immune system gets its receptors back.
This is the quietly clever part of the Glycyx thesis. Repurposing a molecule that already cleared safety trials means starting the oncology story with 544 patients of tolerability data already on the shelf - once-daily oral dosing in the 10 to 15 mg range, no severe adverse events reported. Drug development is mostly the business of things going wrong; starting with a known-safe molecule pointed at a newly-named problem skips a large and expensive chapter.
Axelopran antagonizes peripheral mu-opioid receptors on immune cells - without touching the central receptors that provide pain relief.
With opioid signaling out of the way, T-cells can infiltrate the tumor microenvironment and immune exhaustion eases.
A reawakened immune response restores the efficacy of checkpoint inhibitors across solid tumors - turning "cold" tumors "hot."
Figures are approximate and drawn from published research cited by Glycyx; the bars are illustrative, not a controlled comparison.
Glycyx is run by co-founders who between them cover the three jobs a clinical-stage biotech actually needs: commercial, scientific, and business. CEO Justin Chickles brings a couple of decades across companies including Johnson & Johnson and Purdue Pharma; Lorin Johnson serves as Chief Scientific Officer; David Taggart as Chief Business Officer. Bridget Martell is Chief Medical Officer and Jonathan Moss, MD, PhD - a name associated with the early science of peripheral opioid antagonism - advises on the medical side.
Leads strategy, partnerships, and fundraising, with ~25 years across pharma and startups.
Chief Scientific Officer guiding the axelopran program and its mechanism of action.
Chief Business Officer handling licensing, development strategy, and business operations.
Chickles, Johnson, and Taggart establish the company in San Francisco around the idea of opioid-induced immunodeficiency.
Published research (Mao et al, 2022) links opioid use to a ~50% reduction in checkpoint-inhibitor efficacy across ~4,000 patients.
The company raises a $3.5M tranche to fund clinical development of axelopran.
Axelopran reaches Phase 2b-readiness with an active IND in April 2024, and clinical-grade supply is produced.
Glycyx wins non-dilutive funding for a Phase 2 trial of axelopran with pembrolizumab in recurrent/metastatic head & neck cancer.
The planned clinical program reads as a basket trial - several cancers gathered around one shared enemy rather than one tumor type. Glycyx has described cohorts spanning recurrent/metastatic head and neck squamous cell carcinoma, non-small cell lung cancer, and melanoma, plus a randomized study of standard-of-care immunotherapy with or without axelopran in opioid-using Stage IV patients. The logic is that the mechanism - opioid immune suppression - travels across solid tumors, so the drug should too.
For patients: keep effective pain management without trading away immunotherapy benefit.
For oncologists: a potential add-on that addresses a host-level barrier rather than the tumor alone.
For the field: a test of whether "host-level immune therapy" deserves a seat next to tumor-targeted drugs.
For partners: a de-risked, safety-established molecule with a defined combination path alongside checkpoint inhibitors.
Axelopran first appeared in trials for opioid-induced constipation. Its oncology role is a genuine second act.
Because it's "peripherally restricted," it works on immune cells in the body while leaving brain pain-relief pathways alone.
The entire thesis rests on one number: a ~50% efficacy drop across ~4,000 opioid-using patients.
Despite chasing a major oncology problem, the core team is roughly three people.
It's a San Francisco biopharmaceutical company developing axelopran, a drug meant to reverse opioid-induced immune suppression so cancer immunotherapy works better.
An orally administered, peripherally restricted mu-opioid receptor antagonist. It blocks opioid signaling on immune cells outside the brain without reducing pain relief.
Roughly 45% of immunotherapy patients take opioids for pain, and studies link opioid use to a ~50% reduction in checkpoint-inhibitor efficacy, likely by keeping T-cells out of tumors.
Axelopran is Phase 2b-ready with an active IND (April 2024) and 544 patients of prior safety data. An NIH-backed Phase 2 trial with pembrolizumab is planned in head and neck cancer.
It was founded in 2020 by Justin Chickles (CEO), Lorin Johnson (CSO), and David Taggart (CBO), and is headquartered in San Francisco, California.